A retrospect on the discovery of way-100635 and the prospect for improved 5-HT1A receptor PET radioligands
- 1 July 2000
- journal article
- review article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 27 (5) , 441-447
- https://doi.org/10.1016/s0969-8051(00)00109-8
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Receptor binding characteristics of [
H ]NAD-299, a new selective 5-HT1A receptor antagonistEuropean Journal of Pharmacology, 1998 - Imaging 5-HT1A receptors with positron emission tomographyNuclear Medicine Communications, 1997
- The advantage of using positron emission tomography in drug researchTrends in Neurosciences, 1996
- Visualization and characterization of 5-HT receptors and transporters in vivo and in manSeminars in Neuroscience, 1995
- Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonistBehavioural Brain Research, 1995
- A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635European Journal of Pharmacology, 1995
- Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brainEuropean Journal of Pharmacology, 1994
- WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptorsEuropean Journal of Pharmacology, 1993
- (S)-N-tert-Butyl-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptorsJournal of Medicinal Chemistry, 1993
- Buspirone: Action on serotonin receptors in calf hippocampusEuropean Journal of Pharmacology, 1983